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Vaneowrr. Bririrh Co1rrmbi.n. Cnnodn 
dim had their climieal-arrhythmia induced by pmgrnmmcd stimJ- 
tatton. Rocainamide and prP?aRnone alow Faillo to prevent 
reinduction of Iacbycardii n all. Mexitetine was Fubsquentty 
a&ted to propafenone sml prognmlmed stimulation wa3 repeated. 
The combination of two antiarrhythmic agents has success- 
fully prevented recurrent ventricular tachycardia in a few 
highly selected patients with arrhythmias refractory to either 
agent used alone (l-3). Mexiletine. a class IB agent. has only 
a weak negative inotropic ehct (4) and is hemodynamically 
well tolerated when combined with other antiarrbythmic 
agents. The combination of class tB and class tA agents has 
been repaned (3.5-7) to slow induced ventricular tachycar- 
dia in most cases and to suppress its induction by pm- 
grammeo stimulation in 35% to 50% of patients (U-7). 
There is li!tle information about the combination of class IB 
and IC drugs. hiendes et al. (8) recentlv retwted the effects 
of combining mexiletine ‘vith a wtety of class IC drugs and 
showed enhanced slowing of the rate of ventricutar tachy- 
cardia but no effect on tachycardia induction. 
ihis studv was undertaken to assess whether the combi- 
nation of mexiletine and propafenone. a class IC agent. ic 
effective in preventing the induction of ventricul;lr tachycx- 
dia in patients presenting with sustained ventricular tachy- 
cardia or syncopc who had failed testing with procainamide 
and propafenoo~ alone. 
Methods 
Study patients. Patients were entered into the study if 
they presented with sustained ventricular tachycardia or 
syncope and met either of the following two criteria: 
ii sustained ventricular tachycardia was inducible at base- 
tine elcctropbysiologic study and after treatment with intra- 
venous procainamide alone (15 mgjkg body weigbt) o: oral 
propafenone atone. or 2) patients had spontaneous ventric- 
ular tachycardia while taking one or both of these medica- 
tions. 
thug administration. S!!!dy aarients continued to take 
the same dose of oropafenooe (to a maximal dose of 
‘GIN mglday) with the aadition of mexiletine. Mexitetine 
administration was started at 400 &da:? -xi rhe dose 
increased untit tolerated to a rnaxim~l dose of 800 mgidaj’ in 
three to four divider! doses. The efficacy of this combination 
was dewruined at electrophysiologic study performed ~48 h 
after the start of mexiletine administration. 
Electrocardiographic data. Standard electrocardio- 
graphic (ECG) variables of PR interval, QRS complex dora- 
lion and corrected QT interval (QTc) were measured on the 
ECG obtained during smus rhythm. Results wire compared 
on ECGs obtained while the pnicnt was receiving I) no 
drugs, 2) propafenane alone. and 3; propafenonc and mexi- 
lerine in combination. 
Elertrophysiologic study. All paiients gave wrrtten in- 
formed consent for each elrctrophy*_iologic study ana were 
studied in the fasting state. Each drug was approved for use 
m Canada at rhc tiw of the study and programmed stimu- 
lation techniques were m accord with standard clinical 
oractice. Patients were lightly sedated with intravenous 
&zeparn and fentanyl. Excep; for oigoxin, all antiarrhyd- 
mic agents were dwontinued at least 5 half-lives before the 
control study. Mul!ipolar electrode catheters were intro- 
duced through the right femoral vein under 1% lidncaine 
anesthesia and were posirinned under Ruoroscopic guidance 
at the right vemilcular ap. high right atrium and HIS 
bundle region. Programmed ventricular stimulation was pcr- 
formed with currents of 2.ms pulse width at twice diastolic 
rhrtshold. Signals were recorded by using B filter band width 
of 30 10 50 Hz on a 16.chzmncl Siemens chart recorder at a 
speed of 100 mmlr. An I-heat stimulus train @,I at two or 
three cycle lengths (600.500 and 400 ms) was followed by an 
extrastimulus (S,) late iu diasto!e. The S,S? interval was 
progressively shortened in IO-ms intervals until S, failed to 
capture the ventricle, definmg the right ventricular effective 
re&tory perrod. The S, & then placed at an inrerval of 
30 ms longer thaa the right ventricular effective refractory 
period after S, and a second extrastimulus (S,) was inuo- 
duced late in drastole. The S,S, interral w?s zhortencd by 
IO-ma intervals until S, was refractory. At thr: point. the 
S,S2 interval was short&red hy IO ms. the S2SI in&al u’a, 
lenethened hv 50 rns and the SS, interval win shortened 
until S, wns &ractory. This pro&&e was re&aled until S2 
failed to capture the ventricle at all three stimulus train cycle 
lengths. If ventricular tachycardia was not induced, the 
ventricular catheter was then positioned in the right ventrie- 
ular outflow tract sod the protocol repeated. If ventricular 
tachycardia was again not mduced and the patient had a 
previously documented ventricular arrhythmia. a third ex- 
trdstimulus was added at both rieht ventricular sites. The 
extrastimuli were introduced at progressively earlier inter- 
vals in the manner just described. In patients in whom 
ventricular tachycardia remained noninducible, isoproterc- 
nol infusion was begun and lhe protocol repeated. 
During drug therapy repeat elecirophysiologic studies 
were performed by using the protocol used in the control 
study. Stimulation was undertaken with up to 2 extrastimuli 
from two )ittb ;n those in whom iachycardia was induced by 
1 or 2 extrasttmuli in the control stale. Up to 3 ex:rastimuli 
wcrc used if this level was required in the control state. 
Detinirions. Susrnined venrricular rachycardiu was de. 
fined ac ventricular tachycardia >3O s in duration or requir- 
ing termination because of hemodynamic instability. Nonin- 
ducihihry of ventricular tachycardia was defined ar fdilure to 
induce >5 repetitive ~entrwdar responses with the same 
+wla:ioz prc:occI required to induce the arrhythmia at 
hasc!ine study and with at least double extrdstimuli. 
Siatistical analysis. The data are expressed as mean value 
? SD. Comparison between mean vallres was performed by 
using a Sadent I test and analysis of variance. Differences 
wcrc considered signiticant when the p vahre was <0.05. The 
incidence of hemodynamic compromise was compared 
among the three study states using chi-square analysis. 
Results 
The study group consisted of I5 men and 1 woman 23 to 
78 years of age (mean 60 f 17) with an ejection fraction 
ranging from 14% to 14% (mean 38 ? 18%). Thirteen of these 
patients had coronary artery disease with previous rnyocrw 
dial infarction. one had aortic valve disease. one had or- 
rhythmogenic right ventricular dysplasia and one had nc 
sIructural heart disease (Table I). Thirteen patients nad 
documented ventricular techycardiz and three had cardiac 
syncope before the study. In all patients two to six (median 
three) previous drug trials h&d been unsuccessful. 
Electroeardiographie data. In I2 patienrs. the ECG was 
obtained during sinus rhythm in the control state as well as 
during propafenone and prnpafcnone plus mexileline admin- 
istration. Two patients had a pacemaker and two had spon- 
~aneous ventricular lachycardia during one of the studies, 
preventing data acquisition. Mean values for PR interval, 
QRS duration and QTc interval are shown in Table 2. 
Although the PR and QRS intervals increased with pro- 
pafenone, this difference did not achieve significance. The 
apparent increase in the QTc interval is attributable to QRS 
prolongation. Mexiletine had no other ffect on any variable. 
Ventricular tachycardtt. Ventricular tachycardia was in- 
ducible in 15 patients in the drug-free state. One patient had 
frequent spontaneous ventricular tachycardia in the control 
state and while receiving procainamide or propafenone alone 
and did not undergo studies in these three situations. Afier 
prncilinami~tc cdminirtration. 14 patiexs had inducible rcn- 
tricular tachycardia and 2 had spontaneous tachycardm 
With propafcnone alone. 13 patients had inducible vcmric- 
ular tachycardia and t;le remaimng 3 had spontaneous vcn- 
lricular taehycardw.. The conli~ur&on of the Induced vcn- 
tricular tachycardia was similar to that of the presenting 
tuchycardia in all cases in which u WBE documented. Ven- 
tricular tachycardia was monomorphic in !4 prdenta and 
polymorphic in 2. 
The mean daily dose of propafcnonc was 825 i 130 mg: 
for mexilctine. it was MO * 130 mg. 
Elrctrophysiolagic study resui~. Thr right wn~w:!ur 
e&rive refroctoy period. This interval increnxd from 225 
f 24 ms at baseline to 25X t 30 ms wth propafenone 10 < 
0.05). The addition of mexiletine to proanfeaone did not 
result in any significant change in the effective refractory 
period I255 C 42 ms, p > 0.05). 
Ixducrion of venrric&: mchwwdia Venrrw~lar tachy- 
cardia was uoninducible in three patients (19%) rccciwg the 
propafcnonc-mexile!inc ombination. A fourth patient who 
presented with :mlymorphic ventricular tachycardia and 
Qwe 1. \entricular taehyeardia (VT) cycle length dunng the 
syncopc had asymptomatic bundle branch reentrant xhy- 
contml study. pmpafcnone therapy and rombined prop&none and 
mc.,,letine thempy. Error bars represent s aodard e\iarion. 
cardia (cycle length 500 ms) indsced. In those patients in 
whom ventricular taehvcardia remained inducible. the mean 
cycle length of the taehycardia Increased from 262 i 60 ms Adverse e&m. Hemodynamic deterioration nccessitat- 
at baseline to 390 * 80 ms with the propafcnone-meailetine mg dircc! current shock for cardioversion or defibrillation 
combination (p < O.wOI). Therr was a tendency for the occurred in six patients during the control study, in five with 
induced ventricular tachycardia cycle length to be longer propaienonc and in two with the propaienone-mexiletine 
with combination therapy than with propafcnoue alone (350 combinatinn. Although these events were important for 
f 82 ms), but this ditTcrcncc did not reach stnti~~~czl Tigzif- indi,;Li patients, they did not achievr statistical signili- 
icattce (p > 0.M). Eleven pittients had >50-ms prolongation cance for the group (p > 0.1). 
of the baseline txhycardia cycle length with combination roi!~ <+~p dam The three patients in whom ventricular 
therapy (Fig. I). tachycardta was not induced were discharged on the combi- 
The mode of induction of ventricular tachycardta was 
assessed. In thr baseline study, v :nu-icular ta&cardia was 
nation theraw. Two patients remain on drug therapy at 22 
and 28 months, rcsp&tively. and have been &rhythr& free. 
induced with double cxtrastimuh in I I txitients and triple 
extrastimuli in 2. Double extrastimuli were required ior 
One of these patients is taking 900 m&lay of prop&none 
and 3Oil mglday of mexilettne: the other is taking MO mglday 
induction of ventricular tachycardia in IO patients who were of propafcnonc and 3W m&lay af mexiletine. The third 
unsuccessfully tested with the rrropafc*one-T.eriieiinr com- patient stopped taking all drugs Gter 8 months -*ithout 
biur.ti~a. No paoent who had an unsuccessful test with this ansuIting his physician and has not had rceurrcnt tachycar- 
combination had ventricular tachycardia induced with triple dia for I2 months. 
extrastimuli. The patient who had spontaneous tachycardia The patient in whom slow bundle branch block tachycar- 
in the control state and with eac’l drug alone had veotricular 
tacb;flcardia with loss of conscious&s induced while taking 
dia was inducible was dischargcd on treatment with these 
drugs. but he subsequently refused all dmq therapy and had 
the drug combination. another episode of polymorphous ventricuiar tachycardia. 
Of the three patients in whom ventricular tachycardia He dcvcloped a psychiatric &a&r for which he was 
could not be reinduced with the drug combination. one had counseled. but he declined all therapy and died suddenly. 
four episodes induced in the control state and had sponta- presumably of arrhythmia. 
neow tachycardia with propufcnone alone. The second 
patient required double extrastimtth in the control slate and 
with pmpafcnone alone. The third patient had tachycardia 
with a single extnstimulus in the control state and two Combination therapy with antiarrhythmic drugs has been 
episodes of tachyeardis with double extrastimuli with pro- shown to be effective in animal models 19-l I) and in humans 
pafcnone. In all three patients, tachycardia was nonirdeeihie (1-3.12.13). Combining antiarrhythmic agents may allow 
with double extrastimuli from two sites at multiple pacing 
..- 
lower drug doses of each aw?t. thus rcducutg stdc citccts. 
cycle lengths Wllh the drug eombm.!lon. Electropharmacologic interaction may also enhance drug 
efficacy. The most commonly combined drugs have been 
slas IA and class IB agents !I-3.9.131, suggesting enhanced 
et?icacy fer treatment of ventricular arrhythmias. 
Pharmacoiogic interaction. Propafenone. a class 1C drug. 
binds to the sodium channel in the activated and inactivs!ed 
states and has a slow rate 01 dissociation (14.15). Mexiletine 
hinds preferenhally to the inactivated sodium ciiannel and 
has a fast rate of disrociation (l&17!. In guinea pig papillary 
muscle. me&tine ootentiated the propafenone-induced de- 
crease in maximal rate of depoinriz&n phase iV,,J with- 
out affecting action potential duration (IO). Mexiletine KC.+ 
erated the onset of the use-dependent attenuation of V,,, 
but did no: alter the rccavery kmetics. Combination therapy 
induced a mole pronounceddepression of Vmli, suggest& 
that this drug combination may have synergistic clinical 
effects in slowing conduction velocity and possibly bls eking 
one limb of a potential reentrant cirwit. 
Phnrmscokinelic interaction. Althotieh phnrmacologic 
synergy is ill most bkely explanation for enhanced electro- 
physmlogic Sect. pharmacokinetic interactions cannot be 
excluded. However, mexiletine has a !“w protein-binding 
atliinity. making competitive unbinding of prop_fcnone un- 
likely. Little is known about the effects uf mexilet;r.: on 
hepatic metabohsm, I ^ - c,,c! excretion or binding of other 
d&s. Significant alteration of propafenone blood levels. 
although possible. is unltkely. 
Bei;.oQ;;amir and elrctrophysiologir etTects. The present 
study demonstrates that the combinatton of propafenone and 
mexiletine may bc effectwe in supprwing the induction of 
rzn!+colar tachvcardia in some pltienth whb arrhythmias 
previously found to be refractory to procainamide and 
propafenone administered alone. In those patients in whom 
ventricular ;achycardia could Still be indwed. the tachycar- 
dia ?vas biower and hemodynamic deterioration requiring 
direct current shock was les; frequent. 
Previous studies (18.191 suaeestcd that the likelihood of 
finding a successful antiarrhy%ic drug for patients who 
have an unstcccrsful electrophysiologic test result with 
procainamidc is low. The success rate of the combinatton of 
propafenone and mexiletine in this study is particularly 
significant because these patients had already had UBPW 
cessful elec;mphy+logic test results or had clinical recur- 
rences of their arrhythmia with both procainamide and 
propafenone. 
Slowing of the ventricular tachycardia cycle length -c- 
curred in many patients tested with propafenotw alone and 
further slowing was seen with the combination therapy. 
supporting the Indines of the I” vitro studv. Slowing ef:hc 
tachycardia cycle length with propafenone did not predict 
noninducibility of arrhythmia with the drug combination. 
The abi!ity of combination therapy to slow the tachycardia 
may have resulted in the reduced requirement for electrical 
cardioversion demonstrated in our study. A reduced require- 
ii;eo! for defibrilletion he: Lair ,rported 12.3) with the 
rombmation of meziletinc and class IA agents ana is also 
thoaght to be due to the slowing of the induced tachycardia. 
Combining :ntiarrh;!!xic egcnts to prevent ventricular 
tachycardiamayallowalowerdoseofeach~~entto he used, 
thus reducing side effects while enhancing efficacy. In this 
study, no attempt was made to reduce the dose of pro- 
pafenone when mexiletine was added. Propafenone was well 
tolerated by all patients before the addition of mexiletine and 
the dose of the latter agent was adjusted to avoid side erects. 
Limitations of study. Mexi’4ne was not tested alone and 
the possibility that it may have prevented arrhythmia induc- 
t~on in some of these patients cannot he excluded. However, 
the poor response to other sincle agents after unsuccessfu: 
pro&inamidk therapy makes this p&ibility unlikely (l&19) 
and studies (20) have shown mexiletine alone to be inetTec- 
tive tn pre*xnting reinduction of ventricular tachycardia by 
programmed stimulation. z3lood :rv& of drum. were not 
measured, thus preventing detection of possible phxmsco- 
kinetic interaction. However. blood levels of propafenone 
do not correlate well !vith clinical efficacy (21). Although the 
number of patients in this study was small, the data indicate 
that the combination of mexiktine and propafenone may be 
useful in some patients with arrhythmias that have been 
refractory to testing with these and other antiarrhythmic 
agents. 

